Xbrane’s CEO on the launch of Ximluci in Europe
Together with its partner STADA, the biosimilar company Xbrane Biopharma is currently in the process of launching Ximluci, a biosimilar to the reference drug Lucentis for the treatment of a serious eye disease. In connection with the BioStock Investor Meeting, the company‘s CEO Martin Åmark talked about the product launch, the plans for the upcoming US launch and the licensing plans for the oncology portfolio.
Also watch Martin Åmarks company presentation of Xbrane Biopharma at the BioStock Investor Meeting below:
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.
